Transcatheter Aortic Valve Replacement With Intra-Annular Self-Expanding or Balloon-Expandable Valves: The Multicenter International NAVULTRA Registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cannata Stefano, Sultan Ibrahim, Van Mieghem Nicolas, Giordano Arturo, De Backer Ole, Byrne Johnathan, Tchetche Didier, Buccheri Sergio, Nombela-Franco Luis, Teles Rui Campante, Barbanti Marco, Barbato Emanuele, Amat Santos Ignacio, Blackman Daniel J, Maisano Francesco, Lorusso Roberto, La Spina Ketty, Millin Antonella, Kliner Dustin E, van den Dorpel Mark, Acerbi Elena, Lulic Davorka, Divekar Kaivalya, Cesario Vincenzo, Chavez Solsol Jorge Francisco, Brito Joao, Costa Giuliano, Casenghi Matteo, Fernandez Cordon Clara, Sherwen Amanda, Buzzatti Nicola, Pasta Salvatore, Turrisi Marco, Minacori Michele, Manca Paolo, Nuzzi Vincenzo, Tamburino Corrado, Bedogni Francesco, Gandolfo Caterina, Latib Azeem
Аннотация
OBJECTIVES: This study sought to investigate the 1-year outcomes of transcatheter aortic valve replacement using the intra-annular NAV and the ULTRA THVs.
METHODS: The NAVULTRA (Navitor and SAPIEN 3 Ultra) registry included consecutive patients who underwent transfemoral transcatheter aortic valve replacement at 16 centers with NAV or ULTRA between November 2018 and April 2024. Propensity score matching was used for adjustment. The primary outcomes of interest were all-cause death and the composite of all-cause death, disabling stroke, and hospitalization for heart failure at 1 year.
RESULTS: The overall study cohort included 3,878 patients treated with NAV (n = 1,746) or ULTRA (n = 2,176). The propensity score-matched population resulted in 1,363 pairs. At 1 year, the rate of death from any cause was 9.7% with NAV and 9.9% with ULTRA (adjusted P = 0.585). Similarly, there were no significant differences in primary composite outcome (13.6% in the NAV group and 12.6% in the ULTRA group; adjusted P = 0.218). The rate of new permanent pacemaker implantation (20.6% vs 10.6%; adjusted P < 0.01) and heart failure rehospitalization (4.6% vs 2.8%; adjusted P < 0.05) was higher in NAV group. At 1 year, the use of NAV was associated with higher rates of mild paravalvular leak (OR: 1.53; 95% CI: 1.01 to 2.33; adjusted P < 0.05) but lower mean transprosthetic gradients compared with ULTRA (mean change:-3.90, 95% CI: -4.47 to -3.34; adjusted P < 0.01).
CONCLUSIONS: Both intra-annular THVs were associated with similar 1-year clinical outcomes; however, differences were observed in secondary clinical endpoints and valve hemodynamic performance.